Trials / Withdrawn
WithdrawnNCT04406610
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
Chimeric Antigen Receptor-Modified T Cells for GD2 Positive Recurrent and Metastatic Glioma
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.
Detailed description
Chimeric antigen receptor (CAR) is a recombinant receptor with both antigen-binding and T cell activating functions. Chimeric antigen receptor T cell Immunotherapy has more advantages compared with conventional immunotherapy, especially in dealing with patients of hematologic malignancies and solid malignant tumors.This study design a novel specific Chimeric antigen receptor aiming at GD2 antigen.After CAR-T cell infusion,At periodic intervals, the investigators will evaluate clinical symptoms Improved conditions of this disease.Through this study,the investigators will evaluate the safty and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GD2 CAR-T immunotherapy | Antigen-specific T cell therapy |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2016-08-15
- Completion
- 2016-10-15
- First posted
- 2020-05-28
- Last updated
- 2020-07-16
Source: ClinicalTrials.gov record NCT04406610. Inclusion in this directory is not an endorsement.